<DOC>
	<DOCNO>NCT00129168</DOCNO>
	<brief_summary>Chemotherapy drug use different way stop cancer cell divide stop grow die . Zosuquidar may help daunorubicin cytarabine kill cancer cell make cancer cell sensitive drug . It yet know whether daunorubicin cytarabine effective without zosuquidar treat acute myeloid leukemia .</brief_summary>
	<brief_title>Zosuquidar Combination With Daunorubicin Cytarabine Patients Ages 55-75 With Newly Diagnosed Acute Myeloid Leukemia ( AML )</brief_title>
	<detailed_description>Purpose : Phase I : To Evaluate safety different dos zosuquidar . Phase II : This study design study safety effectiveness zosuquidar give daunorubicin cytarabine newly diagnose AML patient .</detailed_description>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Cytarabine</mesh_term>
	<mesh_term>Daunorubicin</mesh_term>
	<criteria>Newly diagnose acute myeloid leukemia Ages 5575 year Acute promyelocytic leukemia ( FAB M3 ) Patients must receive prior chemotherapy AML . Prior exposure anthracycline Use investigational agent within 4 week prior enrollment study For Phase II : Patients must Pglycoprotein positive</criteria>
	<gender>All</gender>
	<minimum_age>55 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>March 2008</verification_date>
	<keyword>Leukemia , Myeloid</keyword>
	<keyword>Relapse</keyword>
	<keyword>Chemotherapy</keyword>
	<keyword>Zosuquidar</keyword>
	<keyword>Daunorubicin</keyword>
	<keyword>Cytarabine</keyword>
	<keyword>Acute</keyword>
	<keyword>AML</keyword>
	<keyword>Adult AML</keyword>
</DOC>